ASMS 2023: A Look at the Wednesday Morning Oral Session on Drug Discovery and Development

From 8:30–10:30 am, an oral session titled “Drug Discovery and Development: Qualitative and Quantitative Analysis” will be taking place in Grand Ballroom B. Presided over by session chair Veronica Laos of Eli Lilly and Company, this series of six talks will discuss varying analyses of the drug creation process.

At 8:30 am, Matthew Rardin of Amgen, Inc. in South San Francisco, California, will initiate the session with a talk about multi-omic analysis revealing changes in cellular pathways following MARC1 knockdown in mouse models of NASH.

Following this, at 8:50 am, He Zhu of the Dana-Farber Cancer Institute, in Boston, Massachusetts, will discuss the process of deciphering deubiquitinase ubiquitin signaling and substrate degradation by DIA-PASEF.

Next, at 9:10 am, Ruth H. Walker of the Biosciences Institute Faculty of Medical Sciences, in Newcastle University, Newcastle Upon Tyne, NE2 4HH, United Kingdom, will give a talk on developing high-throughput screening MALDITOF MS cellular assays for drug discovery in non-alcoholic fatty liver disease.

The subsequent 9:30 am talk will be led by Lindsay K. Pin of Talus Bioscience in Seattle, Washington, with a focus on simultaneous in situ pharmacological profiling of transcription factors for cancer therapy.

The fifth talk, which will begin at 9:50 am, will be led by Christian T. Madsen of Novo Nordisk A/S in Måløv, Denmark. Madsen’s talk centers around employing mass spectrometry and positional peptide patterns to probe for bioactive peptides.

Finally, Fabien Fontaine of Lead Molecular Design, S.L. in Sant Cugat del Valles, Spain, will give a talk on structural elucidation in drug metabolism and chemical degradation studies for molecules of any size and any high resolution acquisition modes.